- BPH Drugs
- Alpha Blockers
- 5-Alpha Reductase Inhibitors
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Muscarinic Receptor Antagonist (MRA)
- Combination Drug
- BPH Devices
- Prostatic Stents
- Suture Base Implant Systems
- Transurethral RF Thermal Therapy Devices
Benign Prostatic Hyperplasia (BPH) Treatment Market size was valued at USD 11.6 million in 2023 and is expected to grow at a CAGR of 5.6% from 2024 to 2030. BPH, a non-cancerous enlargement of the prostate gland, affects a significant portion of the male population over 50, leading to various urinary symptoms and impacting quality of life. The increasing prevalence of BPH, coupled with the aging global population, drives market growth. Additionally, advancements in drug therapies and minimally invasive devices contribute to market expansion by offering more effective and patient-friendly treatment options. In the BPH Drugs segment, combination therapies combining alpha-blockers with 5-alpha reductase inhibitors have gained traction due to their comprehensive approach to symptom relief. The introduction of novel drug classes like PDE-5 inhibitors for BPH treatment has further expanded the pharmaceutical options available to patients.
In the BPH Devices segment, innovations in minimally invasive technologies such as transurethral RF thermal therapy devices and suture-based implant systems have revolutionized treatment approaches, offering alternatives to traditional surgical interventions. The market is also benefiting from increased awareness about prostate health and improved healthcare access in developing countries. However, challenges such as side effects of certain medications, the high cost of advanced devices, and potential complications from long-term use of some treatments may hinder market growth. The North America region held the major market share in 2023 and is expected to dominate the global BPH Treatment Market in the forecasted years, driven by advanced healthcare infrastructure and high awareness levels.
Benign Prostatic Hyperplasia (BPH) Treatment Market Key Developments:
In May 2022, Teleflex Incorporated announced the launch of the UroLift Advanced Tissue Control (ATC) System. This new system:
In December 2021, Olympus Corporation announced FDA 510(k) clearance for the iTind procedure for treating BPH. This development:
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The increasing prevalence of BPH in aging populations is a significant driver for the market, high disease burden emphasizes the need for effective BPH treatments across various demographics and treatment modalities. Growing patient preference for minimally invasive procedures has spurred innovation in the BPH Devices segment. Treatments like transurethral RF thermal therapy devices and prostatic stents offer alternatives to traditional surgical approaches, often resulting in faster recovery times and reduced risk of complications. The pharmaceutical segment continues to evolve, with combination therapies and novel drug classes gaining traction. The introduction of muscarinic receptor antagonists (MRAs) for BPH treatment has provided new options for patients with overactive bladder symptoms associated with BPH. However, the high cost of some advanced treatments and potential side effects of long-term medication use may hinder market growth in some regions. Additionally, the shift towards online pharmacies as a distribution channel, accelerated by the COVID-19 pandemic, is reshaping the market landscape and patient access to BPH treatments.
Benign Prostatic Hyperplasia (BPH) Treatment Market was valued at USD 11.6 million in 2023 and is expected to grow at a CAGR of 5.6% from 2024 to 2030.
The Benign Prostatic Hyperplasia (BPH) Treatment Market is segmented based on Treatment Type, Distribution Channel, and Geography.
The leading players in the global Benign Prostatic Hyperplasia (BPH) Treatment Market are Johnson & Johnson, Medtronic plc, Boston Scientific Corporation, Teleflex Incorporated, Olympus Corporation, NeoTract, Inc., Urologix, LLC, Endo International plc, GlaxoSmithKline plc, Pfizer Inc., Astellas Pharma Inc., and Merck & Co., Inc.
Historic years considered for the market study are 2019-2022, 2023 is considered as the base year for market estimation, and Seven years forecast is presented from 2024 – 2030.
1. Executive Summary |
2. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Introduction |
2.1.Global Benign Prostatic Hyperplasia (BPH) Treatment Market - Taxonomy |
2.2.Global Benign Prostatic Hyperplasia (BPH) Treatment Market - Definitions |
2.2.1.Treatment Type |
2.2.2.Distribution Channel |
2.2.3.Region |
3. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Benign Prostatic Hyperplasia (BPH) Treatment Market By Treatment Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. BPH Drugs |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. BPH Devices |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6. Global Benign Prostatic Hyperplasia (BPH) Treatment Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Institutional Sales |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Retail Sales |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Online Pharmacies |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global Benign Prostatic Hyperplasia (BPH) Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8. North America Benign Prostatic Hyperplasia (BPH) Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.BPH Drugs |
8.1.2.BPH Devices |
8.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Institutional Sales |
8.2.2.Retail Sales |
8.2.3.Online Pharmacies |
8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.BPH Drugs |
9.1.2.BPH Devices |
9.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Institutional Sales |
9.2.2.Retail Sales |
9.2.3.Online Pharmacies |
9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
9.3.6.Rest of EU |
10. Asia Pacific (APAC) Benign Prostatic Hyperplasia (BPH) Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.BPH Drugs |
10.1.2.BPH Devices |
10.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Institutional Sales |
10.2.2.Retail Sales |
10.2.3.Online Pharmacies |
10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11. Middle East and Africa (MEA) Benign Prostatic Hyperplasia (BPH) Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.BPH Drugs |
11.1.2.BPH Devices |
11.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Institutional Sales |
11.2.2.Retail Sales |
11.2.3.Online Pharmacies |
11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.BPH Drugs |
12.1.2.BPH Devices |
12.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Institutional Sales |
12.2.2.Retail Sales |
12.2.3.Online Pharmacies |
12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.Johnson & Johnson |
13.2.2.Medtronic plc |
13.2.3.Boston Scientific Corporation |
13.2.4.Teleflex Incorporated |
13.2.5.Olympus Corporation |
13.2.6.NeoTract, Inc. (acquired by Teleflex) |
13.2.7.Urologix, LLC |
13.2.8.Endo International plc |
13.2.9.GlaxoSmithKline plc |
13.2.10.Pfizer Inc. |
13.2.11.Astellas Pharma Inc. |
13.2.12.Merck & Co., Inc. |
14. Research Methodology |
15. Appendix and Abbreviations |